Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amylx Pharmaceuticals Inc (AMLX) vs Nasdaq100 ETF (QQQ) Price & Performance

Amylx Pharmaceuticals IncTrade
Nasdaq100 ETFTrade

Price performance (Past 24H)

Key statistics

Amylx Pharmaceuticals Inc vs Nasdaq100 ETF — how do they compare? Amylx Pharmaceuticals Inc trades at $23.6 (market cap $2.64B), while Nasdaq100 ETF trades at $724.54. Which is the better fit depends on your goals.

AMLXQQQ
Market Cap
$2.64B
Sector
Health
52-Week High
$24.19$746.16
52-Week Low
$7.82$558.34
Enterprise Value
$2.39B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amylx Pharmaceuticals Inc

AMLX trades at $23.61, up 4.15% today, with strong analyst support (91% buy ratings) and a $30 consensus price target. The stock shows bullish technical momentum despite negative profitability metrics (ROE -74.73%, ROA -66.25%). Recent Q2 2026 earnings missed expectations, but the company maintains $250.8M cash runway into 2028, supporting its pivotal Phase 3 LUCIDITY trial readout expected August-September 2026.

The investment thesis hinges on successful avexitide clinical outcomes, with potential 2027 launch offering significant upside. Key risks include ongoing financial losses, clinical trial execution, and competitive pressures. Current valuation at 11.02x book value appears stretched given negative earnings, making positive trial results critical for justifying premium pricing.

Nasdaq100 ETF

QQQ trades at $725.07, up 0.59% with a bullish technical signal from moving averages. The ETF shows strong institutional interest with Ferguson Shapiro increasing its position by 2,685.7%. Technical indicators show mixed signals with RSI suggesting mild overbought conditions while ADX indicates strong trend momentum. The Nasdaq-100 tracker benefits from tech sector strength and AI-driven market leadership.

QQQ's outlook remains positive given tech sector momentum and institutional accumulation. Key risks include concentration in mega-cap tech stocks and potential volatility from Fed policy shifts. The ETF's long-term performance record and current technical setup support continued upside potential, though investors should monitor overbought conditions and sector rotation risks.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amylx Pharmaceuticals Inc

Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.

Read more on AMLX

About Nasdaq100 ETF

The ETF is designed to track the performance of the securities and the stocks in the NASDAQ-100 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.

Read more on QQQ